Investigating Paclitaxel Toxicity in Breast Cancer: The Roles of Physical Activity and Body Composition.
Conditions: Breast Cancer; Paclitaxel Adverse Reaction; Chemotherapeutic Toxicity; Chemotherapeutic Agent Toxicity; Body Weight; Physical Inactivity Interventions: Drug: Paclitaxel Chemotherapy Sponsors: Universitair Ziekenhuis Brussel; Vrije Universiteit Brussel; University Ghent Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 29, 2024 Category: Research Source Type: clinical trials
Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
Conditions: Epithelial Ovarian Cancer Interventions: Behavioral: Intermittent Fasting; Drug: Neoadjuvant chemotherapy Sponsors: Case Comprehensive Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL
Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma Interventions: Drug: Vincristine; Drug: Cyclophosphamide; Drug: Dexamethasone; Drug: Venetoclax; Drug: Inotuzumab ozogamicin; Drug: Blinatumomab; Drug: 6-mercaptopurine; Drug: Methotrexate; Drug: Cytarabine; Drug: Prednisone Sponsors: Institute of Hematology& Blood Diseases Hospital, China Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia Interventions: Drug: HMPL-306 Regimen; Drug: Salvage Chemotherapy Regimen Sponsors: Hutchmed Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2024 Category: Research Source Type: clinical trials
TOP 2301: Neoadjuvant Chemo for NSCLC
Conditions: Non Small Cell Lung Cancer Interventions: Drug: Alirocumab; Drug: Cemiplimab; Drug: Chemotherapy Sponsors: Duke University; Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2024 Category: Research Source Type: clinical trials
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
Conditions: Lymphodepleting Chemotherapy; Myeloid Malignancies Interventions: Drug: Cyclophosphamide; Drug: Fludarabine phosphate; Drug: Decitabine Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2024 Category: Research Source Type: clinical trials
Livertoxcicity in Acute Leukemia Patients During Chemotherapy Treatment
Conditions: Liver Toxicity, Chemically-Induced Interventions: Combination Product: Chemotherapy Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2024 Category: Research Source Type: clinical trials
Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life
Conditions: Glioma; Glioma, Malignant Interventions: Diagnostic Test: Resting State Functional Magnetic Resonance Imaging (rs-fMRI); Behavioral: Up-front Motor Rehabilitation; Drug: Up-front Chemotherapy Sponsors: University of Milan; University of Turin, Italy Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer Interventions: Drug: BL-B01D1; Drug: Pemetrexed+Cisplatin or Carboplatin Sponsors: Sichuan Baili Pharmaceutical Co., Ltd.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Conditions: Triple-Negative Breast Cancer Interventions: Drug: BL-B01D1; Drug: Eribulin; Drug: Vinorelbine; Drug: Gemcitabine; Drug: Capecitabine Sponsors: Sichuan Baili Pharmaceutical Co., Ltd.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
Conditions: Non Small Cell Lung Cancer Metastatic; ALK Gene Mutation Interventions: Drug: Lorlatinib Sponsors: Centro di Riferimento Oncologico - Aviano Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials
A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN)
Conditions: Refractory Lupus Nephritis Interventions: Biological: TAK-007; Drug: Chemotherapy Agents Sponsors: Takeda Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Conditions: Relapsed/Refractory KMT2A-r Acute Leukemia; Relapsed/Refractory NUP98-r Acute Leukemia; Relapsed/Refractory NPM1-m Acute Leukemia Interventions: Drug: Ziftomenib; Drug: Cytarabine; Drug: Fludarabine Sponsors: LLS PedAL Initiative, LLC; Kura Oncology Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC
Conditions: Limited-stage Small-cell Lung Cancer Interventions: Drug: Tislelizumab; Drug: Carboplatin injection; Drug: Cisplatin injection; Drug: Etoposide injection Sponsors: Beijing Chest Hospital, Capital Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
Conditions: Advanced Breast Cancer Interventions: Drug: physician ' s choice of chemotherapy sequential Ribociclib combined with NSAI ±OFS; Drug: Ribociclib combined with NSAI±OFS Sponsors: The First Affiliated Hospital with Nanjing Medical University; Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
